Background: Drugs' dialyzability is the degree to which a drug is filtered out of the blood stream during dialysis. This process is influenced by various factors, including properties of the drug and dialysis procedure. As drug experts, pharmacists must pay close attention to drugs' dialyzability when counseling patients on medications to ensure that therapeutic drug concentrations are maintained in the patient's body.
Aim: This study aimed to assess the knowledge of pharmacists working in dialysis centers or hospitals with dialysis wards regarding drugs' dialyzability.
Methodology: A descriptive cross-sectional study was conducted in November 2022. A three-section questionnaire was developed and distributed to 160 pharmacists. It's first section gathered six demographic questions about the participants. The second included 12 questions related to dialysis and drugs' dialyzability, while the third section contained 13 questions about the dialyzability of the most commonly used drugs in dialysis wards.
Result: A total of 141 pharmacists were enrolled, resulting in a response rate of 88.12%. Most of the participants (83.7%) were female, with a mean age of 27.82 ± 4.18 years. About one-third of participants worked in dialysis wards. Surprisingly, only 27% of the pharmacists had fair to good knowledge regarding drugs' dialyzability. There was no significant difference in the knowledge of pharmacists with different age groups, genders, degrees, institutions and years of experience, except for those who had worked in dialysis wards when compared with those who never worked there before.
Conclusion: The analysis of the data indicates the need to improve pharmacists' knowledge, especially for those working or about to work in dialysis wards. Continuous educational programs and workshops can help maintain and enhance knowledge after graduation.



(1) Caroline SZ, Michael GC, Applied therapeutics: the clinical use of drugs, Eleventh ed., Philadelphia : Wolters Kluwer Health, 2018.

(2) Yasir M, Umair A, Imran A. HEMODIALYSIS; acute intradialytic complications found on maintenance hemodialysis in patients at a public hospital Lahore. Prof. Med. J. 2019; 26 (1) https://doi.org/10.29309/TPMJ/2019.26.01.2511.

(3) Aminu KB, Ikechi GO, Mohamed AO, Yeoungjee C, Htay H, Vivekanand J, Marina W, David WJ. Epidemiology of haemodialysis outcomes. Nature Reviews Nephrology. 2022; 18 (6) :378–395. https://doi.org/10.1038/s41581-022-00542-7.

(4) Gary RM, George RA, Arthur JA, William MB, Brian SD, Kai-Uwe E, Thomas G, Darren WG, Bertram K, Frieder K, Jan TK, Ravindra M, Bruce AM, Deborah AP, Franz S, Domenic AS, Lesley AI, Jason GU, Patrick M. Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int.. 2011; 80 (11) :1122–1137. https://doi.org/10.1038/ki.2011.322.

(5) Athena FZ. Understanding renal replacement therapy and dosing of drugs in pediatric patients with kidney disease. Journal of clinical pharmacology. 2012; 52 (1) :134–140, 2012. https://doi.org/10.1177/0091270011415413.

(6) George RB, Nancy AM, 2022 DIALYSIS OF DRUGS, Saline, Michigan, Renal Pharmacy Consultants, LLC, 2022.

(7) Masatoshi T, Yoichi A, Kenichi T. Effect of Haemodialysis on the Pharmacokinetics of Antineoplastic Drugs. Clin. Pharmacokinet. 2004; 43 (8) :515–527. https://doi.org/10.2165/00003088-200443080-00002.

(8) Daiane de OS, Maria CM, Sonia LC, Regina MCP, Alberto C, Rafael S. Pharmaceutical care for patients with persistent asthma: Assessment of treatment compliance and use of inhaled medications. J Bras Pneumol. 2010; 36 (1). https://doi.org/10.1590/s1806-37132010000100005.

(9) Magdalena WN, Piotr N, Marek S. Physicians’ and patients’ valuation of pharmaceutical care implementation in Poznan (Poland) community pharmacies. Saudi Pharm. J. 2014; 22 (6) :537–544. https://doi.org/10.1016/j.jsps.2014.02.012.

(10) Chantale Daifi, Brian F, Pia-Allison R, Jerry Y. Implementation of a Clinical Pharmacist in a Hemodialysis Facility: A Quality Improvement Report. Kidney Med. 2021; 3 (2) :241-247. https://doi.org/10.1016/j.xkme.2020.11.015.

(11) Anwar HS, Ihsan R, Haider S. Adherence and Beliefs to Adjuvant Hormonal Therapy in Patients with Breast Cancer: A Cross-Sectional Study. Iraqi J. Pharm. Sci. 2021; 30 : 31–39. https://doi.org/10.31351/vol30issSuppl.pp31-39.

(12) Lucas MO, Daniella MS, Layissa C. Relation between safe use of medicines and Clinical Pharmacy Services at Pediatric Intensive Care Units. Rev. Paul. Pediatr. 2016; 34 (4) :397–402. https://doi.org/10.1016/j.rppede.2016.04.001.

(13) Ganesh SP, Raja AA, Muhammad AIB, Enti H. The Pharmacist Role In Improving Medication Adherence In Dialysis Patients: A Systematic Review. Syst. Rev. Pharm.2021; 12 (3) : 761–768.

(14) Noor YF, Amenah MM, Suhair M. Evaluation of Community Pharmacists Knowledge, Attitude and Practice towards Modified Release Dosage Forms. Iraqi J. Pharm. Sci. 2022; 30 :40–47. https://doi.org/10.31351/vol30issSuppl.pp40-47.

(15) N. Janus, J. Thariat, H. Boulanger, G. Deray, V. Launay-Vacher. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Annals of Oncology. Oxford University Press. 2010; 21 (7) :1395–1403. https://doi.org/10.1093/annonc/mdp598.

(16) Christo C, Yvonne B, Nikunj V, Anne HN. Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis. Drugs. 2021; 81 (5) :555–574. https://doi.org/10.1007/s40265-021-01469-2.

(17) A. Tokareva, N. Borovkova, I. Polyakova. High dialysis clearance of drugs predicts intradialytic hypertension in hemodialysis patients. Eur. Heart J. 2020; 41 :3325. https://doi.org/10.1093/ehjci/ehaa946.3325.

(18) Panagiotis IG, Theodoros E, Vassilios L. Should We Use Dialyzable β-Blockers in Hemodialysis?. Kidney Med. 2022; 4 (5) :100468. https://doi.org/10.1016/j.xkme.2022.100468.

(19)Raosoft, Inc. Raosoft Inc. Sample size calculator; 2017. Available: http://www.raosoft.com/ (accessed Apr. 15, 2023).

(20) Harold JM, Marcy LMC, Debra KO, Marcia AW, Gerald MR, Walter LB, Timothy KN, Sudarshan H, Richard SM. Factors associated with medication-related problems in ambulatory hemodialysis patients, Am. J. Kidney Dis. 2003; 41 (2) : 386–393. https://doi.org/10.1053/ajkd.2003.50048.

(21) Harold JM, Debra KD, Richard SM. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol. 2003; 4 (10) :1–7. https://doi.org/10.1186/1471-2369-4-10.

(22) Alvin T. Beta blocker dialyzability and effectiveness in chronic hemodialysis patients. Electronic Thesis and Dissertation Repository. 2016; 4053.

23) Syed ASS, Muhammad HT. Evaluation of pharmacist’s knowledge regarding chronic kidney disease. Arch. Pharm. Pract. 2020; 11 (4) :1–8.

(24) Lolwa A, Maha A, Salmeen DB, Syed W, Abdulrahman A, Sultan MA, Mohamed NA, Ziyad A. Assessment of Pharmacists’ Knowledge and Practices towards Prescribed Medications for Dialysis Patients at a Tertiary Hospital in Riyadh Saudi Arabia. Healthcare. 2021; 9 (9) :1098. https://doi.org/10.3390/healthcare9091098.

(25) Azianey Y, Yook CC, Yasmin MH. Awareness and prevalence of mammography screening and its predictors - A cross sectional study in a primary care clinic in Malaysia. Asian Pacific J. Cancer Prev. 2014; 15 (19) :8095–8099. https://doi.org/10.7314/APJCP.2014.15.19.8095.

(26) Ensaf YA, Wassan J, Amani A, Lama H, Ahmad Q, Huda YA. Shedding light on pharmacists’ knowledge of kidney stones’ etiology and treatment. Pharm. Pract. (Granada). 2022; 20 (3) : 01–10. https://doi.org/10.18549/PharmPract.2022.3.2712.

(27) Retno AH. How education on nutrition increases knowledge of hypertension among the adolescents, GHMJ (Global Heal. Manag. Journal). 2022; 5 (1) :58–63. https://doi.org/10.35898/ghmj-51601.

(28) Meryem DA, Nevzat B, İffet Y. Evaluation of the Knowledge, Practices, Attitudes and Barriers of Community Pharmacists toward Oral Health and Dental Care in North Cyprus. J. Res. Pharm. 2023; 27 (3) : 957–966. https://doi.org/10.29228/jrp.375.